This article, published in Getting the Deal Through, reviews the legislation that creates the pharmaceutical regulation framework in Italy, particularly with regard to mergers and acquisitions, anticompetitive conduct, product development and licensing agreements, and marketing agreements.
Pharmaceutical Antitrust in Italy: 32 Answers
By Martino Sforza on September 19, 2016
Posted In Healthcare Antitrust, Italian Developments
Tags: AIFA, anticompetitive exchanges of information, antitrust violation, Community Code Relating to Medicinal Products for Human Use, competition law, EU, Generic drugs, Italian Medicines Agency, marketing authorization, Ministry of Economic Development, Ministry of Health, Ministry of the Economy and Finance, National Health Service, pharmaceutical product pricing, technology transfer agreements, TFEU, Treaty on the Functioning of the European Union, TTBER
Martino SforzaMartino Sforza focuses his practice on advising European and international clients before the European Commission, the national competition and regulatory authorities, and the civil and administrative courts. He has extensive experience in assisting international clients on antitrust, distribution, consumer protection, data privacy rules and issues related to regulated markets.
Related Posts
- The Case of Ophthalmic Drugs in Italy and France: A Lesson to Learn – Parallel Antitrust Investigations and Cooperation Between National Competition Authorities
- Annual European Competition Review 2019
- An Increased Cooperation in Enforcement Activity: The Italian Competition Authority and the Italian Medicines Agency Sign a Memorandum of Understanding
- Getting the Deal Through: Pharmaceutical Antitrust 2014
- European Commission Adopts Revised Competition Regime for Technology Transfer Agreements
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- Going ‘Green’—What Does That Mean? FTC Proposes Revisions to Green Guides
- EU Commission Adopts New Merger Simplification Package
- CMA Blocks Microsoft’s Acquisition of Activision Blizzard; ‘Game Over’ for Behavioral Remedies?
- DOJ’s Labor Market Prosecution Against Aerospace Employees Dismissed; Alleged Market Allocation Not Within Per Se Rule
- Negative Option Offers: How the FTC’s Proposed Rule Could Affect Your Business
